Keyword: cGMP


Catalent Opens Cell Therapy Facility in Belgium

13.12.2022 -

Catalent has opened a new commercial-scale cell therapy manufacturing facility at its European center of excellence for cell therapies in Gosselies, Belgium.


Cambrex Takes Snapdragon Chemistry

23.11.2022 -

US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based...


Change of Ownership for US CDMO Alcami

10.11.2022 -

UK specialist healthcare investor GHO Capital Partners and US investment firm The Vistria Group have entered into an agreement to buy a controlling interest in US CDMO...


Ariceum and AmbioPharm in Peptide Partnership

07.11.2022 -

Ariceum Therapeutics, a Berlin-headquartered private biotech developing radiopharmaceutical products for the diagnosis and systemic targeted certain hard-to-treat cancers...


Recipharm Bolsters Blow-Fill-Seal Capabilities in France

31.10.2022 -

Swedish multinational CDMO Recipharm has bolstered its sterile filling capabilities at its facility in Kaysersberg, France, by installing Lab+ continuous automated...


Catalent to Invest $12 Million at Kansas City

26.10.2022 -

Catalent has announced a $12 million expansion program to increase biologics CGMP analytical capabilities at its flagship facility in Kansas City, Missouri.


Evotec Enhances Rare Disease Focus with Central Glass Buy

30.08.2022 -

German CDMO Evotec is to acquire compatriot company Central Glass Germany from Japanese owner Central Glass for a nominal price of €1. The transaction, which remains...


Cambrex to Upgrade Generic API Manufacturing Facilities at Milan Site

26.10.2018 - East Rutherford, NJ/USA-based Cambrex Corporation is investing approximately $3 million to increase the capacity and efficiency of one of its cGMP manufacturing facilities at its...